[Intravesical radioimmunotherapy of carcinoma in situ of the urinary bladder after BCG failure]

In failure to respond to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ (CIS) of the urinary bladder, radical cystectomy remains the mainstay after BCG failure.

The aim of this pilot study was to evaluate tolerability and safety of the α‑emitter radioimmunoconjugate instillation in patients after BCG failure.

Nine patients were included. After emptying the bladder via a transurethral catheter, Bi-213-anti-EGFR-mAb was instilled. Treatment was terminated by emptying of the radioimmunoconjugate from the bladder 120 min after instillation. Efficacy was evaluated via endoscopy and histology 6 weeks after instillation.

All patients showed excellent toleration of the treatment without any side effects. Treatment resulted in complete eradication of tumor cells in 3 patients and persistent tumor detection in the other 6 patients.

Intravesical instillation of Bi-213-anti-EGFR-mAb is a promising therapeutic option for treatment of in situ bladder cancer after BCG failure for patients who wish to preserve the bladder.

Der Urologe. Ausg. A. 2016 Jan 24 [Epub ahead of print]

M E Autenrieth, T Horn, F Kurtz, K Nguyen, A Morgenstern, F Bruchertseifer, M Schwaiger, M Blechert, C Seidl, R Senekowitsch-Schmidtke, J E Gschwend, K Scheidhauer

Klinik und Poliklinik für Urologie, Klinikum rechts der Isar, TU München, München, Deutschland. ., Klinik und Poliklinik für Urologie, Klinikum rechts der Isar, TU München, München, Deutschland., Institut für Transurane der Europäischen Kommission, Karlsruhe, Deutschland., Klinik und Poliklinik für Nuklearmedizin, Klinikum rechts der Isar, TU München, München, Deutschland.